Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended access momelotinib in myelofibrosis
NL-OMON52629Phase 2Active, not recruiting
- Sponsor
- Sierra Oncology
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of mivavotinib in primary myelofibrosis (PMF) and myelofibrosis (MF) (5 arms), sponsored by Sierra Oncology. Primary endpoints: Safety, Overall survival and 1 more. Started May 2019; status: active, not recruiting.
02
Drugs
mivavotinib
03
Conditions
primary myelofibrosis (PMF)myelofibrosis (MF)
Beyond the preview
Go deeper on NL-OMON52629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52629.